[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP]

Objective: To evaluate the efficacy and safety of obinutuzumab combined with glucocorticoid-based therapy in patients with relapsed immune thrombotic thrombocytopenic purpura (iTTP). Methods: This study analyzed the efficacy and adverse reactions of four patients with relapsed iTTP who were treated with a combination of obinutuzumab and glucocorticoids to assess the effectiveness and safety of the treatment. Results: All four patients had a history of multiple relapses and had previously undergone treatment with rituximab and bortezomib. Three patients exhibited additional autoantibodies. Following the combined therapy, all patients achieved clinical remission, with ADAMTS13 activity returning to normal levels and inhibitors testing negative. During a median follow-up period of 11 months (range: 3-17 months), all patients maintained sustained remission. No severe adverse events were reported during treatment or follow-up. Conclusion: The combination of obinutuzumab and glucocorticoid-based therapy is effective and safe for treating relapsed iTTP.